<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Microbiology">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Microbiology</JournalTitle>
      <Issn>2008-3289</Issn>
      <Volume>16</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>04</Month>
        <Day>19</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Antibacterial and antibiofilm activities of diclofenac against levofloxacin-resistant Stenotrophomonas maltophilia isolates; emphasizing repurposing of diclofenac</title>
    <FirstPage>166</FirstPage>
    <LastPage>175</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Ingy</FirstName>
        <LastName>El-Soudany</LastName>
        <affiliation locale="en_US">Department of Microbiology and Immunology, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria, Egypt</affiliation>
      </Author>
      <Author>
        <FirstName>Ibrahim</FirstName>
        <LastName>Abdelwahab</LastName>
        <affiliation locale="en_US">Department of Microbiology and Immunology, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria, Egypt</affiliation>
      </Author>
      <Author>
        <FirstName>Marwa</FirstName>
        <LastName>Yakout</LastName>
        <affiliation locale="en_US">Department of Microbiology and Immunology, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria, Egypt</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>10</Month>
        <Day>21</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>10</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background and Objectives: Stenotrophomonas maltophilia is an opportunistic pathogen causing nosocomial infections. Diclofenac is an anti-inflammatory drug that is considered a non-antibiotic drug. This study assessed the antibacterial and antibiofilm effects of diclofenac and levofloxacin/diclofenac combination against levofloxacin resistant isolates.
Materials and Methods: Minimum inhibitory concentration was determined using broth microdilution method for levofloxacin, diclofenac, and levofloxacin/diclofenac combination. Biofilm forming capacity and biofilm inhibition assay were determined. Relative gene expression was measured for efflux pump genes; smeB, and smeF genes and biofilm related genes rmlA, spgM, and rpfF without and with diclofenac and the combination.
Results: Diclofenac demonstrated MIC of 1 mg/ml. The combination-with &#xBD; MIC diclofenac- showed synergism where levofloxacin MIC undergone 16-32 fold decrease. All the isolates that overexpressed smeB and smeF showed a significant decrease in gene expression in presence of diclofenac or the combination. The mean percentage inhibition of biofilm formation with diclofenac and the combination was 40.59% and 46.49%, respectively. This agreed with biofilm related genes expression investigations.
Conclusion: Diclofenac showed an antibacterial effect against Stenotrophomonas maltophilia. The combination showed in-vitro synergism, significant reduction in biofilm formation and in the relative level of gene expression. Furthermore, it can potentiate the levofloxacin activity or revert its resistance.</abstract>
    <web_url>https://ijm.tums.ac.ir/index.php/ijm/article/view/4452</web_url>
    <pdf_url>https://ijm.tums.ac.ir/index.php/ijm/article/download/4452/1652</pdf_url>
  </Article>
</Articles>
